Inhibiting the NLRP3 inflammasome has been observed to enhance metabolic health and lifespan in HFD‐induced obesity models [15], positioning NLRP3 as a promising therapeutic target at the intersection of metabolic dysregulation, neuroinflammation, and AD pathology. This evidence concerns the gene NLRP3 and obesity due to melanocortin 4 receptor deficiency.